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Abstract
Objectives: Technical complications are a known hazard in veno-venous
extracorporeal membrane oxygenation (vvECMO). Identifying these complications
and predictive factors indicating a developing system-exchange was the goal of the
study.
Methods: Retrospective study on prospectively collected data of technical
complications including 265 adult patients (Regensburg ECMO Registry, 2009-
2013) with acute respiratory failure treated with vvECMO. Alterations in blood flow
resistance, gas transfer capability, hemolysis, coagulation and hemostasis
parameters were evaluated in conjunction with a system-exchange in all patients
with at least one exchange (n583).
Results: Values presented as median (interquartile range). Patient age was 50(36–
60) years, the SOFA score 11(8–14.3) and the Murray lung injury Score 3.33(3.3–
3.7). Cumulative ECMO support time 3411 days, 9(6–15) days per patient.
Mechanical failure of the blood pump (n55), MO (n52) or cannula (n51) accounted
for 10% of the exchanges. Acute clot formation within the pump head (visible clots,
increase in plasma free hemoglobin (frHb), serum lactate dehydrogenase (LDH),
n513) and MO (increase in pressure drop across the MO, n516) required an
urgent system-exchange, of which nearly 50% could be foreseen by measuring the
parameters mentioned below. Reasons for an elective system-exchange were
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worsening of gas transfer capability (n510) and device-related coagulation
disorders (n532), either local fibrinolysis in the MO due to clot formation (increased
D-dimers [DD]), decreased platelet count; n524), or device-induced
hyperfibrinolysis (increased DD, decreased fibrinogen [FG], decreased platelet
count, diffuse bleeding tendency; n58), which could be reversed after system-
exchange. Four MOs were exchanged due to suspicion of infection.
Conclusions: The majority of ECMO system-exchanges could be predicted by
regular inspection of the complete ECMO circuit, evaluation of gas exchange,
pressure drop across the MO and laboratory parameters (DD, FG, platelets, LDH,
frHb). These parameters should be monitored in the daily routine to reduce the risk
of unexpected ECMO failure.
Introduction
Over the last 40 years, extracorporeal membrane oxygenation (ECMO) has been
used to support adult patients with respiratory or cardiac failure who are unlikely
to survive conventional mechanical ventilation [1]. Pivotal progress in
extracorporeal technology, encouraging results of the efficacy and economic
assessment of ECMO for severe adult respiratory failure (CESAR) trial [2, 3] and
good outcomes of ECMO patients during the recent H1N1 influenza pandemic
[4, 5] have contributed to a resurgence of interest in ECMO therapy [6, 7].
Improvements in ECMO circuitry, pump and oxygenator technology permit safer
perfusion for longer periods of time. Respective clinical benefit of veno-venous
(vv) ECMO support was reviewed by Combes and coworkers [8]. However, none
of the recently published systematic reviews and pooled analyses of retrospective
studies focused on the development of technical complications while on ECMO
[9].
This is the first experience report by a single ECMO center to evaluate early
technical complications on ECMO, which might be relevant for a system-
exchange.
Materials and Methods
The Regensburg ECMO database was queried for all consecutive patients on
vvECMO (January 2009 to December 2013, n5265). Only patients with at least
one system-exchange and an ECMO support duration of more than 48 hours
were included. Among patients needing multiple ECMO treatments, only the first
was included. Prospectively collected physical and laboratory parameters allowed
a retrospective analysis of the reasons for a system-exchange in 83 patients. Ethical
approval for publication of this retrospective analysis and need for informed
consent was waived by the Ethics Committee of the University of Regensburg, as
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all devices are approved for clinical use, no personalized data and only routine
laboratory parameters were used. Patient characteristics are shown in Table 1.
Indications for vvECMO are shown in Table 1 and in file S4.
Standard treatment for ECMO patients
When ECMO is initiated, mechanical ventilation is reduced based on the blood
gases, aiming for a fraction of inspired oxygen (FiO2) of ,60%, peak inspiratory
pressure,26–28 cmH2O, and positive end expiratory pressure (PEEP) aiming for
lung recruitment according to underlying disease usually .10 cmH2O [10]. The
tidal volume (TV) is kept between 3–6 ml/kg ideal bodyweight according to peak
pressure and the proportion of arreated lung tissue as indicated on a
computerized tomography (CT) scan. The respiratory rate (RR) is kept between
10–30/min. Arterial blood gases (under stable conditions) are drawn every
Table 1. Patient data and characteristics before ECMO.
All No exchange System-exchange p-value
Patients (n) 265 182 83
Age (years) 50 (36–60) 50 (37–61) 50 (36–60) 0.844
Females (n; %) 90; 34 59; 32 31; 37 0.518
BMI (kg * m-2) 27.8 (24.7–33.1) 28.1 (24.8–32.9) 27.5 (23.9–34.2) 0.545
Ventilation (days) 1.0 (1.0–6.0) 1.0 (1.0–5.3) 2.0 (1.0–6.5) 0.431
SOFA score 11.0 (8.0–14.3) 12.0 (8.0–15.0) 11.0 (8.0–13.0) 0.067
LIS 3.33 (3.33–3.67) 3.33 (3.33–3.67) 3.33 (3.33–3.67) 0.660
ARF (n; %) 60; 22 55; 30 5; 6 #0.001
NE (mg/kg/min) 0.26 (0.10–0.51) 0.27 (0.10–0.51) 0.22 (0.08–0.53) 0.425
PaO2/FiO2 (mmHg) 65 (52–85) 65 (51–84) 69 (52–86) 0.554
PaCO2 (mmHg) 64 (51–80) 63 (50–79) 64 (54–88) 0.252
apH 7.24 (7.15–7.34) 7.23 (7.13–7.33) 7.24 (7.15–7.35) 0.453
TV (ml) 470 (396–562) 477 (399–565) 455 (358–560) 0.447
TV/kg pred. BW (ml/kg) 5.6 (4.2–6.7) 5.6 (4.4–6.7) 5.3 (3.8–6.7) 0.413
Minute ventilation (l/min) 10.6 (8.3–12.6) 11.0 (8.6–12.6) 10.5 (7.9–12.6) 0.517
PIP (cm H2O) 35 (30–39) 35 (30–39) 35 (30–40) 0.813
PEEP (cm H2O) 15 (13–18) 15 (13–18) 15 (13–18) 0.505
ECMO indication 1 0.001
1 (n; %) 150; 57 92; 51 58; 70
2 (n; %) 53; 20 45; 25 8; 10
3 (n; %) 33; 12 28; 15 5; 6
4 (n; %) 29; 11 17; 9 12; 14
Data are presented as median (interquartile range) except for females and acute renal failure. SOFA, Sequential Organ Failure Assessment; LIS, Murray
lung injury score; apH, arterial pH value; PaCO2, partial pressure of arterial carbon dioxide; PaO2/FiO2, ratio of partial pressure of arterial oxygen and
fraction of inspired oxygen; PIP, peek inspiratory pressure; PEEP, positive end-expiratory pressure; TV, tidal volume; BMI, body mass index; ARF, acute
renal failure; NE, Norepinephrine.
1ECMO indications: 1, primary lung failure (bacterial, viral, fungal, aspiration pneumonia and H1N1 infection); 2, sepsis with secondary lung failure; 3, trauma
with ARDS; 4, other pathologies (eg. pulmonary fibrosis, pulmonary hypertension, pulmonary emboli, extensive bronchiectasis, pulmonary bleeding,
tracheal laceration).
doi:10.1371/journal.pone.0112316.t001
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4–6 hours. The ECMO blood flow, FiO2 and PEEP are adjusted to maintain an
arterial oxygen saturation of .90%. The sweep gas flow rate, TV and RR are
adjusted according to the arterial partial pressure of carbon dioxide (PaCO2),
aiming for a normal pH. As sweep gas in vvECMO, 100% O2 is used to utilize
maximal O2 transfer capacity. Hemoglobin is kept >8–9 g/dl and platelet count
.20/nl. The anticoagulation protocol was based on intravenous heparin
application. In patients without an elevated bleeding risk, an activated partial
thromboplastin time (aPTT) of 60 seconds was maintained, and in patients with a
moderately increased bleeding risk an aPTT of 40 to 50 seconds was used. In
trauma patients with severe or multiple bone fractures, or patients with bleeding
diathesis (thrombocytopenia, disseminated intravascular coagulopathy [DIC],
etc.), ECMO support was started without administering heparin for up to 7 days,
relying on the heparin or phosphorylcholin coating of the system. APTT was
controlled and readjusted at least twice daily (details see [10, 11]). The following
lab values were drawn daily and as necessary: ECMO blood gases, complete blood
count, coagulation including D-Dimers (DD), plasma free hemoglobin (frHb),
basic metabolic panel, magnesium, ionized calcium, and phosphorous.
Respiratory parameters included peak inspiratory pressure (PIP), PEEP, TV,
minute ventilation and RR. In addition, blood products used, plus dosages of
norepinephrine and heparin were documented. A chest radiograph or CT scan
was performed when indicated.
ECMO systems and measurements of function
Miniaturized ECMO systems consist of an electrical drive unit, a blood pump,
MO and tubing. Six different ECMO-systems were used: (PLS-System [n5112],
Cardiohelp HLS-set advanced [n551], Quadrox-ID Pediatric oxygenator +
Rotaflow pump [n54], Maquet Cardiopulmonary, Hirrlingen, Germany;
Hilite7000LT oxygenator + DP3 pump [n547], Medos Medizintechnik, Stolberg,
Germany; iLA-activve-system [n515], Novalung, Heilbronn, Germany; ECC.05
system [n536], Sorin Group, Modena, Italy). The main differences between the
ECMO systems used were the types of blood pumps and biocompatible coatings
(PLS-system, Rotaflow 5 centrifugal pump, Heparin based Bioline-coating;
Cardiohelp-system, Rotassist 5 integrated centrifugal pump, Heparin based
Bioline-coating; Hilite-system, Deltastream, DP3 5 diagonal pump, Heparin
based Rheoparin-coating; ECC.05-system, Revolution 5 integrated centrifugal
pump, Phosphorylcholin-coating), as well as the design of the MO (hollow fiber
packing density, winding technique, gas exchange area). The gas exchange
membrane is identical for all systems used and was made of polymethylpentene
(PMP) (Membrana, Wuppertal, Germany). In case of technical complications the
whole ECMO circuit (tubing, MO, blood pump), except for the cannulas, was
exchanged. Cannulas were seleced independent of the type of ECMO system
(single-lumen cannula (n5191, Maquet), single dual-lumen cannula –
AvalonElite bi-caval dual lumen catheter (n555, Maquet), single dual-lumen
cannula - NovaportTwin (n519, Novalung). The systems and cannulas most
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commonly used were described earlier [10]. The extracorporeal support was
initiated with a blood flow of approximately 1.5–2 l/min and a sweep gas flow of
1–3 l/min. Thereafter, blood flow was adjusted according to arterial oxygen
saturation (SaO2), and gas flow according to PaCO2 and pH level.
Transmembrane pressure drop was defined as the difference between pressure at
the inlet and outlet of the MO (dpMO5pMOin – pMOout) [12]. Blood gases at
the device inlet and outlet were also analyzed (Radiometer ABL800 FLEX,
Bronshoj, Denmark).
Technical complications demanding an acute system-exchange
Mechanical failure was defined as leakage at the MO, connectors or pump head.
Acute clot formation usually affects the MO or the pump head [13]. Major clots
within the MO (acute oxygenator thrombosis, AOT) caused an acute increase in
the dpMO, accompanied by a decrease in blood flow at the same pump speed
[12]. Pump head thrombosis (PHT) can be indicated by a sudden sound change
of the blood pump, technically-induced hemolysis [14, 15, 16] and/or a decrease
in platelet count. Differential diagnosis resulting in elevated frHb, such as
powerful aspiration of the blood sample, excessive suction due to cannula
malposition (mostly combined with high negative inflow pressures, inadequate
high pump speed proportionately to blood flow), continuous renal replacement
therapy, thrombosis or larger hematomas have to be ruled out.
The approach to an acute system-exchange is detailed in file S4.
Technical complications demanding an elective system-exchange
Worsening of gas exchange capability
Prolongation of ECMO support and the existence of a coagulation disorder
promote the progression of clot formation within the circuit (especially within the
MO). Thrombotic, fibrin or cellular deposits on the surface of the gas exchange
membranes worsen the gas transfer capability of the MO [12], ultimately
requiring an elective system-exchange.
In the present study, worsened gas exchange capability was defined as follows:
(1) A significant decrease in the partial pressure of O2 in the blood at the outlet of
the MO (pO2 postMO) of more than 50% compared to the initial value and
(2) An elevation of the partial pressure of CO2 in the blood at the outlet of the
MO (pCO2 postMO) over 40 mmHg at high gas flow rates (>10 l/min)
Device-induced coagulation disorder
Coagulation was monitored by measuring activated prothrombin time (aPT),
aPTT, fibrinogen (FG), antithrombin III (AT III), DD and platelet count. Markers
for a device-induced coagulation disorder were an otherwise unexplainable (e.g.
DIC, thrombosis, pulmonary embolism, trauma, surgery) increase in the levels of
DD from ,10 mg/dl to 25–35 mg/dl [17] (fibrinolysis in the MO), or an
otherwise unexplainable increase in DDs and a decrease in FG concentration
Technical Complications during Veno-Venous ECMO
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(,200 mg/dl) (device-induced hyperfibrinolysis) with subsequent improvement
after exchange. Thus, device-induced coagulation disorder is presumptive until
the exchange. These markers were mostly accompanied by a decrease in platelet
count and a diffuse unaccountable bleeding tendency before system-exchange,
which normally reversed after exchange.
Suspected infection of the ECMO circuit
Another reason for an elective system-exchange was suspicion of circuit infection
[18, 19], which was based on clinical observation, positive blood cultures, increase
in inflammatory parameters (C-reactive protein [CRP], leukocytes, fever) without
attributable focus and a diffuse, unaccountable bleeding diathesis. No routine
infection surveillance (e.g. blood cultures at defined days) was performed.
Statistics
Data are expressed as median (25–75 percentile) and were analyzed with the
Wilcoxon-signed-rank test (SigmaStat 3.1, Systat Software, San Jose, CA, USA).
Data were analyzed for normality (Kolmogorov-Smirnov test) and homogeneity
of variance (Levene). Intergroup differences were compared using the Friedman
test for repeated measures analysis of variance (ANOVA) by ranks, with post-hoc
Dunn’s Method for multiple comparison versus control (time of system-
exchange). P-values #0.05 indicated a significant difference.
Results
Study population
Indications for vvECMO were primary lung failure in 68% and secondary lung
failure in 32%. 46 patients had a platelet count of ,80/nl before inclusion, and 67
patients displayed signs of DIC (aPTT of .60 sec, reduced aPT, AT III, FG and
elevated DD levels). All but 25 patients depended on norepinephrine, and 22%
presented with acute renal failure, defined as the need for renal replacement
therapy. Patient characteristics before ECMO are summarized in Table 1.
Eighty-three patients (31%) required one or more system-exchanges due to
technical complications (Figure 1). Patient data and characteristics before ECMO
of both groups (Table 1) were comparable, except that patients with a system-
exchange had less renal failure pre-ECMO (p#0.001), the SOFA score tended to
be lower (p50.067), and the reason for ARDS was more often primary lung
failure and less frequently trauma-related lung failure (p50.001). In both groups,
respiratory (e.g. PEEP, PIP, TV, minute ventilation, RR) or coagulation
parameters (aPTT, aPT, FG, DD, AT III, LDH, platelets) and dosages of heparin
or norepinephrine pre-ECMO were comparable (see file S1). Patients requiring at
least one system-exchange had a longer ECMO support duration (p#0.001), total
ventilation time (p#0.001), residence time in the intensive care unit (ICU)
(p#0.001) and a higher risk of renal failure requiring renal replacement therapy
Technical Complications during Veno-Venous ECMO
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during ECMO (p50.028) (Table 2). Despite prolongation of ECMO support and
implantation of 2 to 5 MOs, there was no difference in mortality between both
groups (p50.113) (Table 2). Comparing patients requiring an acute (37/83) and
elective system-exchange (46/83), those requiring an acute system-exchange
presented with more severe respiratory acidosis (Table 3) and had a shorter
working time of the first MO (p50.023). Patients requiring an elective system-
exchange presented with significantly higher CRP values before ECMO therapy,
tended to have longer durations of ECMO support (p50.095), more often
required several MOs (p50.079) and were ventilated longer (p50.045). However,
during and after ECMO support, the consumption of blood products and
outcome parameters did not differ significantly between acute and elective
exchanges, and in particular mortality was not increased (Table 4). Furthermore,
Figure 1. Retrospective analysis of reasons for acute and elective system-exchange during vvECMO. Acute exchanges were all events that required
an immediate intervention of perfusionists. Mechanical failure was defined as leakage at the MO, pump head problems, dysfunction of the pumpdrive,
cannula or circuit rupture. Acute clot formation within the MO caused a severe increase in the pressure drop across the MO (dpMO) followed by a decrease
in blood flow, while acute clot formation in the pump head was indicated by a dramatic increase in plasma free hemoglobin concentration. Suspected
infection based on clinical observations (see text). Progressive clot formation was observed in almost all remaining MOs, which caused a worsened gas
exchange capability of the MO (decrease in pO2 postMO, increase in pCO2 postMO, increase in sweep gas flow) and an alteration in coagulation parameters
(increase in D-dimer levels, decrease in fibrinogen levels and decrease in platelet counts).
doi:10.1371/journal.pone.0112316.g001
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there were no differences with respect to anticoagulation, or coagulatory and
inflammatory parameters before system-exchange (see file S2).
Technical complications on ECMO
Figure 1 provides an overview of relevant technical complications on ECMO.
Acute system-exchanges
Mechanical failure
Eight patients required an urgent system-exchange due to mechanical failure. A
blood leakage at the gas outlet port of a Medos-MO, or at the inlet connector of a
PLS-MO made system-exchange inevitable. Failure of blood pumps was caused by
electrical failure of the pump drive bridged by use of a hand crank (n53), material
defect of the plastic housing (n51), or imbalance of the propeller within the
pump head that produced abnormal noise (n51). In one patient an air leakage of
a bicaval dual lumen cannula (AvalonElite, Maquet) was documented after 30
days. Intense head movements may have caused the partial cannula rupture.
Urgent clamping and a system stop averted further sequelae. There was no circuit
or tubing rupture.
Pump head thrombosis
PHT (n513) was indicated by a significant increase in the levels of frHb (10 [4–
15] -fold, p#0.001) before the exchange, and a significant decrease thereafter (6
[4–18] -fold, p#0.001) (Figure 2). Clots within each pump head were
documented after removal. In 6/13 patients, increased frHb levels could already be
Table 2. Patient data during and after ECMO support.
All No exchange System-exchange p-value
Patients (n) 265 182 83
Stay in ICU (days) 25 (16 – 38) 21 (14–34) 34 (24–46) #0.001
Intubation (days) 20 (13–32) 16 (11–26) 30 (20–43) #0.001
ARF (n; %) 51; 19 28; 15 23; 28 0.028
Amount of MOs 1 2.0 (2.0–3.0) #0.001
Cumulative support time (days) 3411 1538 1873
Support time 1st MO (days) 8 (6–10) 9 (6–12) 0.073
ECMO duration (days) 9 (6–15) 8 (6–10) 20 (14–27) #0.001
Successful weaning (n; %) 200; 75 143; 79 57; 69 0.113
Died on ECMO (n; %) 65; 25 39; 21 26; 31 0.113
RBC/days ECMO 0.25 (0.00–0.66) 0.20 (0.00–0.67) 0.31 (0.15–0.57) 0.180
FFP/days ECMO 0.00 (0.00–0.25) 0.00 (0.00–0.20) 0.00 (0.00–0.26) 0.463
PC/days ECMO 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.05) 0.019
Data are presented as median (interquartile range) except for successful weaning and acute renal failure on ECMO. MO, membrane oxygenator; ICU,
intensive care unit; RBC, red blood cells; FFP, fresh frozen plasma (1 FFP contains 230 ml plasma); PC, platelet concentrate (1 PC contains 250 ml and 2–
461011 thrombocytes); ARF, acute renal failure.
doi:10.1371/journal.pone.0112316.t002
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seen one day before PHT (day 2 before PHT, 55 [49–60] mg/dl; day 1 before PHT,
143 [117–266] mg/dl, p50.031). Patients without system-exchange showed
significantly less frHb after a comparable support time.
Acute oxygenator thrombosis
AOT was verified by a significant increase in the ratio of dpMO/blood flow before
exchange (2.6 [2.1–4.0] -fold, p#0.001), followed by a subsequent drop after
exchange (3.2 [2.0–5.2] -fold, p#0.001) (Figure 2). In all other patients with acute
system-exchanges, no increase in dpMO/blood flow was noted. Only in 1 patient
with an elective system-exchange (due to suspicion of infection) was an increase
Table 3. Patient data and characteristics before ECMO comparing acute vs. elective system-exchange.
Acute Elective p-value
Patients (n) 37 46
Age (years) 50 (36–58) 50 (36–61) 0.657
Females (n; %) 12; 32 19; 41 0.547
BMI (kg * m22) 26.8 (23.9–34.6) 27.7 (23.9–33.1) 0.887
Ventilation (days) 1.0 (1.0–4.0) 2.0 (1.0–9.0) 0.350
SOFA score 11.0 (7.8–13.3) 11.0 (8.0–13.0) 0.652
LIS 3.33 (3.00–3.67) 3.67 (3.33–3.67) 0.196
ARF (n; %) 1; 2.7 4; 8.7 0.375
NE (mg/kg/min) 0.24 (0.07–0.51) 0.21 (0.08–0.56) 0.812
PaO2/FiO2 (mmHg) 70 (52–89) 65 (54–80) 0.677
PaCO2 (mmHg) 71 (57–103) 64 (53–73) 0.039
apH 7.20 (7.12–7.27) 7.29 (7.19–7.37) 0.005
TV (ml) 450 (350–560) 477 (390–565) 0.495
TV/kg pred. BM (ml) 5.01 (3.76–6.17) 5.68 (3.87–7.80) 0.205
Minute ventilation (l/min) 9.0 (6.4–12.2) 11.0 (9.2–13.4) 0.025
PIP (cm H2O) 33 (30–40) 35 (31–38) 0.582
PEEP (cm H2O) 14 (12–19) 15 (13–18) 0.529
Platelets pre (/nl) 178 (100–371) 206 (103–283) 0.647
Hemoglobin (g/dl) 10.8 (9.1–13.0) 9.9 (8.6–11.5) 0.110
CRP pre (mg/l) 107 (36–206) 177 (108–250) 0.041
Leukocytes (/nl) 11.8 (9.0–19.9) 12.9 (7.5–21.2) 0.927
ECMO indication 1 0.910
1 (n; %) 26; 70 32; 70
2 (n; %) 2; 5 6; 13
3 (n; %) 3; 8 2; 4
4 (n; %) 6; 16 6; 13
Data are presented as median (interquartile range) except for females, acute renal failure. SOFA, Sequential Organ Failure Assessment; LIS, Murray lung
injury score; apH, arterial pH value; PaCO2, partial pressure of arterial carbon dioxide; PaO2/FiO2, ratio of partial pressure arterial oxygen and fraction of
inspired oxygen; PIP, peek inspiratory pressure; PEEP, positive end-expiratory pressure; TV, tidal volume; BMI, body mass index; ARF, acute renal failure;
NE, norepinephrine; CRP, c reactive protein.
1ECMO indications: 1, primary lung failure (bacterial, viral, fungal, aspiration pneumonia and H1N1 infection); 2, sepsis with secondary lung failure; 3, trauma
with ARDS; 4, other pathologies (eg. pulmonary fibrosis, pulmonary hypertension, pulmonary emboli, extensive bronchiectasis, pulmonary bleeding,
tracheal laceration).
doi:10.1371/journal.pone.0112316.t003
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in dpMO/blood flow by a factor of 3.1 seen. This is probably a result of an
exchange before an AOT happened due to progressive thrombosis obstructing
main parts of the oxygenator.
In 11/16 patients with AOT, DD levels were elevated before AOT (31 [23–35]
mg/dl) and declined within 2 days after the system-exchange (13 [6–31] mg/dl,
p50.016). The other 5/16 patients had a sudden AOT missed by routine testing of
DD. There was only a trend towards a decreased platelet count (2 days before
AOT, 161 [76–300]/nl; day of AOT, 145 [74–286]/nl, not significant), which
improved in 6/11 patients after exchange. In addition, in 8/11 patients, the gas
transfer capability of the MOs decreased before AOT (53 [45–59]% decrease in
pO2 postMO; higher levels of CO2 postMO (40 [32–48] mmHg) at high gas flow
rates of 10 [9–11] l/min). Additionally, 2 of 4 patients receiving activated
coagulation factor seven while on ECMO developed an AOT requiring a system-
exchange.
Elective system-exchanges
Suspected circuit infection
In four patients (5%) the system was exchanged due to suspected infection. In one
patient with Landouzy sepsis, mycobacteria were identified microscopically in the
MO after exchange. Another MO was colonized with Enterococcus spp. verified
after ex-vivo long-term incubation with culture medium. Clinical course and
septic history of two patients demanded an exchange due to suspected circuit
infection. These patients developed a diffuse, unaccountable bleeding diathesis
after long-term ECMO support (15–18 days) that ceased after system-exchange.
Table 4. Patient data during and after ECMO support of system-exchange patients.
Acute Elective p-value
Patients (n) 37 46
Stay in ICU (days) 32 (19–43) 38 (24–47) 0.106
Intubation (days) 23 (16–43) 32 (23–45) 0.045
ARF on ECMO (n; %) 10; 27 13; 33 0.903
Amount of MOs 2.0 (2.0–2.0) 2.0 (2.0–3.0) 0.079
Cumulative support time (days) 744 733
Support time 1st MO (days) 7.0 (5.0–10.3) 9.5 (7.0–13.0) 0.023
ECMO duration (days) 17.0 (11.8–26.0) 22.0 (15.0–30.0) 0.095
Successful weaning (n; %) 28; 76 29; 63 -
Died on ECMO (n; %) 9; 17 17; 29 0.320
RBC/days ECMO 0.24 (0.00–0.72) 0.32 (0.25–0.56) 0.147
FFP/days ECMO 0.00 (0.00–0.01) 0.00 (0.00–0.33) 0.054
PC/days ECMO 0.00 (0.00–0.01) 0.00 (0.00–0.06) 0.488
Data are presented as median (interquartile range) except for successful weaning and acute renal failure on ECMO. MO, membrane oxygenator; ICU,
intensive care unit; RBC, red blood cells; FFP, fresh frozen plasma (1 FFP contains 230 ml plasma); PC, platelet concentrate (1 PC contains 250 ml and 2–
461011 thrombocytes); ARF, acute renal failure.
doi:10.1371/journal.pone.0112316.t004
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Furthermore, elevated inflammatory parameters tended to decrease after system-
exchange (day of/after exchange; leukocytes: 15.6 (9.3–17.2)/nl/14.6 (8.2–14.8)/nl;
CRP: 147 (109–236) mg/dl/95 (92–110) mg/dl). In one patient norepinephrine
dosage increased before system-exchange (5-fold; on day of exchange, 0.35 mg/kg/
min) and dropped by a factor of 15 after MO replacement.
Progressive clot formation and worsening of gas transfer
Larger clots could be detected by visual control. Additionally, daily monitoring of
gas transfer data, coagulation and hemolysis parameters allowed early identifica-
tion of MOs with progressive clot formation and worsened gas transfer efficiency
(n542, 51%).
In ten patients worsening of gas transfer capability of the MO was the reason
for a system-exchange. Despite an increase in gas flow rate, pCO2 postMO
increased significantly (.40 mmHg), while pO2 postMO was reduced, opposed to
patients (n536) without system-exchange after a comparable support time (
Figure 3).
Figure 2. Pump head thrombosis (top, A) and acute oxygenator thrombosis (bottom, B). (A) Alterations
in plasma free hemoglobin concentration in patients with pump head thrombosis one day before, at system-
exchange and one day thereafter (n513, black dots). (B) Alterations in pressure drop across the oxygenator
(dpMO) normalized by blood flow in patients with acute oxygenator thrombosis one day before, at system-
exchange and one day thereafter (n516, black dots). Circles in both graphs: Patients without system
exchange and a comparable support time of the MO (>12 days, n536) were used as control group. Since the
system-exchange was necessary after 9 (6–12) days (Table 2), values at day 9 after starting ECMO therapy
were set as ‘‘day 0’’ and days 21 and 1 depicted accordingly. Data are presented as median and interquartile
range. *, p#0.05 compared to day 0 (refers to black dots); 1, p#0.001 compared to patients without system
exchange (circles).
doi:10.1371/journal.pone.0112316.g002
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The ventilatory aggressiveness (PIP, TV, minute ventilation, FiO2) rose slightly
visually, without reaching statistical significance (see file S3). Immediately after
the exchange, gas transfer data improved significantly and ventilatory aggres-
siveness decreased visually. In half of the patients, worsened gas exchange was
accompanied by an alteration of coagulation parameters. Levels of DD increased
in 5 patients from 14 (6–34) to 34 (32–35) mg/dl. FG concentration decreased in
one patient (253 to 98 mg/dl). Platelet count declined in 3 patients from 193 (88–
261)/nl to 53 (42–82)/nL. Removal of the MO resulted in a reduction of DD levels
(13 [5–16] mg/dl, not significant) and delayed increases in FG concentration and
platelet count over the next 5 days (not significant). In addition, 6 patients
showed an increase in frHb levels before system-exchange (61 [30–85] mg/dl to
136 [119–196] mg/dl) that declined thereafter.
Device-related coagulation disorder
Progression of a device-related coagulation disorder was the reason for an elective
system-exchange in the remaining 32 patients, which were divided into two
groups:
Eight patients presented with a device-induced hyperfibrinolysis. As shown in
Figure 4, the FG concentration decreased significantly below the normal value of
200 mg/dl, accompanied by an increase in DD levels within four days before
system-exchange. This was in contrast to patients (n536) without system-
exchange after a comparable support time. The platelet count decreased, but
without reaching significance. The patients in this group showed a diffuse,
otherwise unaccountable bleeding tendency. After exchange, coagulation nor-
malized and bleeding diathesis was reduced. Thus, a device-related hyperfibri-
nolysis was reversible by a system-exchange. Gas exchange of respective MOs was
only minimally affected (data not shown).
The remaining 24 patients had a mainly local fibrinolysis in the MO due to
progressive clot formation. As shown in Figure 5, these also presented with a
significant increase in DD levels and a decrease in platelet counts (not significant)
within 3 to 4 days before system-exchange, as opposed to patients without system-
exchange after a comparable support time. However, the FG concentration
remained unchanged, although 40% of these patients developed bleeding
complications. Furthermore, in seven patients gas transfer capability worsened
before exchange (40% decrease in pO2 postMO [n53] and higher levels of pCO2
postMO [38–43 mmHg] despite high gas flow rates [6–10 l/min]). In 5 MOs the
dpMO increased moderately (1.8 [1.4–2.2] -fold, p50.001). In one patient, frHb
levels were slightly increased. Exchange of the MO reversed the changes in DDs
and platelets, improved gas transfer capability of the MO, reduced frHb levels and
normalized dpMO (2.0 [1.6–2.4] -fold decrease, p50.018).
Technical complications of different ECMO systems
An overview of technical complications for the different systems is shown in
Table 5. Due to large differences in sample size, statistical analysis was not
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performed and conclusions have to be drawn cautiously. The PLS-system was
used most frequently (42%) as it was the first system commercially available.
Technical complications leading to a system-exchange were seen in about 30% of
the ECMO treatments and were independent of the ECMO system used.
Mechanical failure was a rare complication and mainly seen in PLS- and HL-
systems. The CH- and ECC-systems were exchanged in about 60% of cases due to
acute clot formation in the pump head or acute oxygenator thrombosis, whereas
the HL-system was exchanged electively in 79%. Support with an HL-system
showed more ECMO-induced coagulation disorders. WGT of the MO was only
documented in 12% (n510) of the exchanged systems, and 60% were related to
the PLS-MOs. Pump head thrombosis (n513) was documented for the PLS-
system (n55, 14%), CH-system (n55, 28%), ECC-system (n52, 22%) and for
the iLA-activve system (n51, 17%).
Figure 3. Worsened gas exchange capability as a reason for an elective system-exchange. Timeline of
respective values before and after sytem-exchange, ‘‘day 0’’5 system-exchange. Patients with system-
exchange (black dots, n510). Despite an increase in gas flow rate (100% O2) (top, A), the partial pressure of
CO2 at the outlet of the MO (pCO2 postMO) increased significantly (.40 mmHg) (middle, B). The oxygenation
capability (pO2 postMO) decreased (middle, C). ECMO blood flow remained unchanged (bottom, D). After
system-exchange, gas exchange data improved significantly. Circles in all graphs: Patients without system-
exchange and a comparable support time of the MO (>12 days, n536) were used as control group. Since the
system-exchange was necessary after 9 (6–12) days (Table 2), values at day 9 after starting ECMO therapy
were set as ‘‘day 0’’ and depicted accordingly. Data are presented as median and interquartile range. *,
p#0.05 compared to day 0 (refers to black dots). a, p#0.001; b, p#0.01; c, p#0.05 compared to patients
without system-exchange (circles).
doi:10.1371/journal.pone.0112316.g003
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Discussion
The most common technical complication with ECMO is clot formation [20].
This retrospective review detailing technical reasons for an ECMO system-
exchange in 83/265 patients showed that life-threatening acute mechanical ECMO
failure occurred in 10%, and an acute thrombosis of the oxygenator or blood
pump in 35%, of which more than half of the cases showed preceeding alterations
in gas exchange, laboratory values or an increased resistance of the MO. 55% of
the system-exchanges could be done electively due to worsening of gas transfer or
device-related coagulation disorders. Daily monitoring of gas exchange and
pressure drop in the MO, as well as coagulation and hemolysis parameters allowed
identification of developing complications in the majority of cases (see Figure 1
and Figure 6). Consequently, the number of acute system-exchanges can be
decreased and the imminent system-exchanges could be performed during regular
working hours and not on an emergency basis. Infection of the circuit seems to be
a rare complication, but should be considered when elevated inflammatory
parameters are observed, or the patient develops unaccountable bleeding diathesis
after long-term ECMO support.
Figure 4. Device-induced hyperfibrinolysis as a reason for an elective system-exchange. Timeline of
respective values before and after sytem-exchange, ‘‘day 0’’5 system-exchange. Patients with system-
exchange (black dots, n58): (B) Fibrinogen (FG) concentration decreased significantly below the normal
value of 200 mg/dl, while (A) levels of D-dimers visually increased and (C) platelet count decreased (both not
statistically significant). After system-exchange the coagulation disorder could be stopped. Circles: Patients
without exchange and comparable support time (>12 days, n536). Data at day 9 after starting ECMO therapy
were set as ‘‘day 0’’, other values depicted accordingly. Data are presented as median and interquartile range.
*, p#0.05 compared to day 0 (refers to black dots). Differences between patients with and without exchange
on respective days (a, p#0.001; b, p#0.01; c, p#0.05).
doi:10.1371/journal.pone.0112316.g004
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Since the first application of ECMO in adults with ARDS [21], types and rates
of complications occurring on ECMO have influenced the outcome of these
critically ill patients [9]. The incidence of various mechanical complications
during ECMO support in adults can generally be classified into pump failure (4.7–
20%), MO failure (21%) and blood clots within the system (3.2–22%) [9, 13, 22],
all described in the literature as acute events. Especially events such as AOT and
PHT are rarely predictable and the resultant acute emergency might endanger the
ECMO patient. The substantial technological improvements of the ECMO circuits
(e.g. small foreign surface, heparin coating of the entire ECMO system), as well as
intensified circuit management in our ECMO center have reduced the incidence
of acute complications. AOT and PHT accounted for 35% of the complications
and were foreseeable in nearly 50% of the cases. Nevertheless, technical
complications occurred that cannot be foreseen (such as leakage of the MO or
failure of the blood pumps), but remained infrequent events (10%). There were
no circuit or tubing ruptures. An electrical or mechanical pump drive dysfunction
was seen in 3 patients and was bridged by a hand crank. Only in one patient was a
Figure 5. Clot formation and local fibrinolysis in the MO as a reason for an elective system-exchange.
Timeline of respective values before and after sytem-exchange, ‘‘day 0’’ 5 system-exchange. In 24 patients
(black dots), the MO was exchanged after a significant increase in D-dimer levels (A) without relevant
alteration of fibrinogen (FG) levels (B). At the same time, platelet count decreased (C). After exchange, D-
dimer concentration decreased and platelet counts remained stable. Circles: Patient population without
exchange and comparable support time (>12 days, n536). Data at day 9 after starting ECMO therapy were
set as ‘‘day 0’’, other values depicted accordingly. Data are presented as median and interquartile range. *,
p#0.05 compared to day 0 (refers to black dots). Differences between patients with and without exchange on
respective days (a, p#0.001; b, p#0.01).
doi:10.1371/journal.pone.0112316.g005
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rupture of the membrane of a dual-lumen Avalon cannula caused by intense head
movements of the patient seen, resulting in an air embolism in the ECMO circuit.
Two of four patients receiving activated coagulation factor seven while on
ECMO needed an acute system-exchange due to oxygenator thrombosis. Thus,
activated coagulation factor seven on ECMO should only be given for severe live-
threatening intractable bleeding.
Neither elective nor acute system-exchange affected the mortality of our
patients. In subgroup analyses, patients with a system-exchange compared to
those without spent longer time on ECMO, which was probably the primary
reason for the need for a system-exchange. A higher incidence of acute renal
failure during extracorporeal support seen in these patients was probably also
caused by the longer duration of their critical illness.
Table 5. Overview of technical complications for the different ECMO systems.
ECMO systems All PLS CH HL ECC Others
Type of membrane PMP PMP PMP PMP PMP
Biocompatible coating Heparin (Bioline) Heparin (Bioline) Heparin (Rheoparin) Phosphoryl-cholin Heparin
MO exchange-surface
(m2)
1.8 1.8 1.9 1.2
Heat exchanger material,
surface (m2)
Polyurethan 0.6 Polyurethan 0.6 Polyurethan 0.45 Steel 0.14
Type of blood pump Centrifugal
(Rotaflow)
Centrifugal inte-
grated (Rotassist)
Diagonal (Deltastream
DP3)
Centrifugal integrated
(Revolution)
All patients, n (% of all) 265 112 (42) 51 (19) 47 (18) 36 (14) 4 (2)b, 15 (6)a
Patients with exchange,
n (% of all patients)
83 (31) 36 (32) 18 (35) 14 (30) 9 (25) 1 (25) b, 5 (30)
a
Acute exchange 37 (45) 15 (42) 11 (61) 3 (21) 5 (56) 3 (50)
Mechanical failure 8 (10) 5 (14) 0 (0) 2 (14) 0 (0) 1 (17)a
Cannula 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (17)
Pump 5 (6) 4 (11) 0 (0) 1 (7) 0 (0) 0 (0)
MO 2 (2) 1 (3) 0 (0) 1 (7) 0 (0) 0 (0)
Acute clot formation 29 (35) 10 (28) 11 (61) 1 (7) 5 (55,5) 2 (33)
Pump head 13 (16) 5 (14) 5 (28) 0 (0) 2 (22,2) 1 (17)a
MO 16 (19) 5 (14) 6 (33) 1 (7) 3 (33,3) 1 (17)a
Elective exchange 46 (55) 21 (58) 7 (39) 11 (79) 4 (44) 3 (50)
Progressive clot
formation
42 (50) 19 (53) 7 (39) 9 (64) 4 (44) 3 (50)
Worsening of gas transfer 10 (12) 6 (17) 1 (6) 1 (7) 0 (0) 2 (33)a+b
Device-related coagula-
tion disorder
32 (39) 13 (36) 6 (33) 8 (57) 4 (44) 1 (17)a
Suspected infection 4 (5) 2 (5) 0 (0) 2 (14) 0 (0) 0 (0)
PLS 5 PLS-System and CH 5 Cardiohelp-System, Maquet Cardiopulmonary, Hirrlingen, Germany. HL 5 Hilite7000LT oxygenator-System, Medos
Medizintechnik, Stolberg, Germany. ECC 5 ECC.05 system, Sorin Group, Modena, Italy. Others: aiLA-activve-system, Novalung, Heilbronn, Germany;
bQuadrox-ID Pediatric oxygenator + Rotaflow pump, Maquet Cardiopulmonary, Hirrlingen, Germany. PMP 5 Polymethylpenten. Data are presented as n
(%).
doi:10.1371/journal.pone.0112316.t005
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An elective system-exchange was often multifactorial, but mainly due to a
device-related coagulation disorder and worsening gas exchange efficiency of the
MO. Device-related coagulation disorders, which account for 50% of the system-
exchanges in our cohort, can be divided into mainly local fibrinolysis due to clot
formation in the MO and device-induced hyperfibrinolysis. Both are often
accompanied by a drop in platelet count, worsening of gas exchange and a diffuse
bleeding tendency, all of which can be reversed by a system-exchange. Local
fibinolysis is a weak criterion for an oxygenator exchange. However, in 29% of
cases it is associated with worsening of gas transfer of the MO, in 40% with a
diffuse bleeding tendency, and can progress to a device-induced hyperfibrinolysis
associated with bleeding complications often requiring the substitution of blood
products. This puts the patient at risk to transfusion-associated side effects and
generates costs which have to be weighed against the costs and risks of a system-
Figure 6. Flowchart for detecting and managing technical complications on ECMO. Not all predictors have to be present. Differential diagnoses always
have to be ruled out before pathologic values can be attributed to a failing ECMO system. Different types of failure can appear together and the decision for
making an exchange is often multifactorial. Therefore, usually irrespective of the leading cause of technical failure, a complete system-exchange is done, as
seen in this study. If respective components are available and only one single technical failure is present, it is also possible to exchange only the failing
component.
doi:10.1371/journal.pone.0112316.g006
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exchange, since the system-exchange can reverse the device-related coagulation
disorder. Furthermore, since a device-related coagulation disorder is the main
reason for a system-exchange, and the rate of transfused blood products is quite
low in our ECMO cohort, an earlier exchange might reduce bleeding, the need for
transfusions/substitution of blood products and thus reduce patient risk and save
resources. However, the increased efficacy of this strategy must be proven in a
prospective trial.
Worsening of gas transfer led to a system-exchange in ten patients. Gas transfer
inside the MO is a complex process [23, 24], and CO2 removal is more efficient
than oxygenation due to the higher solubility and faster diffusion properties of
CO2 [25]. Although a minimum rate of fresh gas flow is necessary to oxygenate
blood sufficiently, increasing the gas flow rate further will not lead to substantial
improvement in oxygenation, but merely reduce PaCO2 [1]. Worsened gas
exchange led to a significant increase in gas flow over time. In our experience, an
increase in gas flow over 12 l/min did not improve gas transfer. An increase in
blood flow might also improve O2 transfer and CO2 removal. However, an
increase in blood flow rate is also accompanied by an increased risk of mechanical
blood cell trauma. In our experience, a decrease in pO2 postMO of more than 50%
compared to the initial value, and an elevation of pCO2 postMO above 40 mmHg
at high gas flow rates (>10 l/min) are threshold values that indicate worsened gas
transfer capability and demand an elective system-exchange unless ECMO
weaning within a short time is possible. If the gas transfer is only moderately
reduced, it is possible to use the MO for prolonged periods of time with some
fibrin/clots in the circuit. Worsening of gas transfer as the main exchange criterion
accounted for only 12% of the system-exchanges, but it often accompanied other
reasons for system-exchange. Hence the criteria for an elective exchange were
most often multifactorial, e.g. coagulation disorder and worsening of gas transfer
capability, plus increase in ventilatory aggressiveness, with ECMO weaning being
considered impossible within the next several days.
Since fibrin deposition and clot formation are the main reasons for worsening
of gas transfer, early detection might help prevent sudden loss of MO function.
Visual control of the MO and pump head is limited because the clots are often
localized in non-accessible parts of the MO. However, multidetector computed
tomography (MDCT) allows the detection of thrombotic deposits in the non-
visible regions of the MO [26]. Nevertheless, such technology is not yet clinically
established. This study showed that monitoring of gas transfer data (gas flow,
blood flow, O2 and CO2 transfer capacity), the pressure drop across the MO and
of DD might facilitate early identification of respective diffusion barriers.
Colonization of the gas exchange membrane with gram-positive bacteria such
as enterococci [19] or staphylococci [18] is an indication for a system-exchange.
However, verification of suspected infection while on ECMO is difficult. Even in
cases of infection/colonization of foreign material, blood cultures often remain
negative while on antibiotic therapy. In this study, only four patients with septic
diseases received a new system due to suspicion of microbiological colonization
that could be proven in two cases after disassembly of the MOs. In the other two
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patients the suspicion rose clinically. A rise in inflammatory parameters without
clinical source and an unaccountable diffuse bleeding diathesis might be induced
by a system/MO infection and might trigger a system-exchange. Overall, microbial
contamination of the ECMO circuit remained an infrequent event in our ECMO
center, as the insertion and nursing of the insertion sites is done under strict
sterile conditions, and the ECMO circuit is, except for dialysis, not used for other
purposes (e.g. administration of i.v. medications).
There were no important differences regarding the technical complications
between the different ECMO systems, albeit absolute numbers were low and
conclusions have to be drawn cautiously.
To our knowledge, this is the first study that reviewed gas transfer data, MO
pressures, coagulation and hemolysis parameters over time and their relevance for
predicting an ECMO system-exchange (Table 6, Figure 6). Finally, the decision to
exchange the ECMO system was routinely based on the combination of the above-
mentioned laboratory parameters, ventilator parameters, worsening of gastransfer
and increase in dpMO. Over the last 5 years, the number of system-exchanges per
year remained unchanged (25–30%), of which about half of the exchanges were
based on acute events.
Limitations of this study include its retrospective character, the subsumption of
data from six different ECMO systems, and being based only on a single-center
experience report. Unfortunately, the collection of a control group with only acute
system-exchanges failed.
Conclusions
Technical complications remain critical during ECMO therapy and occured in
about 30% of the ECMO treatments. 45% of these system-exchanges had to be
done urgently, whereas the remaining could be done electively. In 10%
unpredictable mechanical complications, and in 5% a suspected infection of the
device as a rare complication were the reasons for a system-exchange. Clot
formation in the MO with worsening of gas transfer and device-related
coagulation disorder, as well as clot formation in the pump head leading to
hemolysis accounted for 85% of the technical complications. Control of the gas
exchange capability and pressure drop across the MO, as well as monitoring of
coagulation and hemolysis parameters over time allow for earlier identification of
these complications and can reduce emergency exchanges.
Key messages
Unpredictable acute mechanical ECMO failure occurred in 10% of the system-
exchanges.
Daily monitoring of gas transfer and pressure drop of the MO, coagulation
(DD, FG, platelets) and hemolysis (frHb, LDH) parameters allow for earlier
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identification of developing complications, which can decrease the need for
emergency system-exchanges.
Device-related coagulation disorder can be reversed by a system-exchange.
Infection of the circuit seems to be an infrequent complication.
Supporting Information
File S1. Coagulation, hemolysis, inflammation, anticoagulation, ventilation
and gas exchange parameters in all patients with and without system-exchange.
Description of data: Timeline of coagulatory parameters (AT III in %, aPTT in
sec., aPT in %, D-dimers in mg/l, Fibrinogen (FG) in mg/dl, Platelet count/nl),
inflammatory parameters (Leukocyte count/nl, C-reactive protein (CRP) in mg/l),
hemolysis parameters (free Hemoglobin (frHb) in mg/l, Lactatdehydrogenase
(LDH) in U/l), Noradrenalin consumption in ug/min/kg bodyweight, Heparin
administration in U/h/kg bodyweight, ventilatory parameters (minute ventilation
in l/min, respiratory rate in breaths/min, tidal volume (TV) in ml, positive
endexspiratory pressure (PEEP) in cmH2O, peak inspiratory pressure (Pmax) in
cmH2O, fraction of inspired oxygen (FiO2) and arterial blood gas values (PaO2/
FiO2 in mmHg, hemoglobin in g/dl, PaO2 in mmHg, PaCO2 in mmHG, apH) in
all patients with and without system-exchange. Data are presented as median and
interquartile range.
doi:10.1371/journal.pone.0112316.s001 (PDF)
File S2. Coagulation, hemolysis, inflammation and anticoagulation before
acute or elective system-exchange. Titel of data: Description of data: Timeline of
Table 6. Summary of technical ECMO failure and diagnosis.
Type of failure Monitoring Parameter Acceptable value on ECMO Value suggesting malfunction
Oxygenator thrombosis Visual inspection No/minimal clot formation Pronounced/subtotal clotting
dpMO (mmHg)/ECMO blood
flow (l/min)
Device dependent [15] 30–50% increase in dpMO
DDimers ,10 mg/l .25–30 mg/l
platelets .50/nl Continuous or rapid decrease
Device-related coagulation
disorder
Fibrinogen .200 mg/dl ,200 mg/dl
Gas exchange failure PO2 post MO .400 mmHg ,200 mmHg
PCO2 post MO (with 10–12 l/min
sweep gas flow)
,30 mmHg .40–45 mmHg or PCO2 pre MO – PCO2 post
MO,5 mmHg
Clots in pumphead LDH ,350 U/l Rapid and substantial increase (.1000 U/l)
Free Hb ,50–100 mg/l Rapid and substantial increase (.300 mg/l)
potentially platelets .50/nl rapid decrease
Sound of the pump Normal silent noise Abnormal noise/vibration of pump head
Type of ECMO failure and predictors with acceptable values during ECMO and values suggesting failure. These are not solely pathognomonic and not all
predictors have to be present in specific types of ECMO failure. Differential diagnoses always have to be ruled out before pathologic values can be attributed
to a failing ECMO system. Different types of failure can appear together and a decision for a system-exchange is often multifactorial.
doi:10.1371/journal.pone.0112316.t006
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coagulatory parameters (AT III in %, aPTT in sec., aPT in %, D-dimers in mg/l,
Fibrinogen (FG) in mg/dl, Platelet count/nl), inflammatory parameters
(Leukocyte count/nl, C-reactive protein (CRP) in mg/l), hemolysis parameters
(free Hemoglobin (frHb) in mg/l, Lactatdehydrogenase (LDH) in U/l),
Noradrenalin consumption in ug/min/kg bodyweight and Heparin administration
in U/h/kg bodyweight before acute and elective system-exchange. Data are
presented as median and interquartile range.
doi:10.1371/journal.pone.0112316.s002 (PDF)
File S3. Settings of mechanical ventilation and arterial blood gases of the 10
patients with an elective system-exchange due to worsening of gas transfer.
Description of data: Timeline (4 days before system-exchange until 3 days after
exchange) of arterial PO2 and PCO2, (both in mmHg), peak inspiratory pressure
(PIP in cm H2O), positive endexspiratory pressure (PEEP, in cmH2O), tidal
volume (TV, in ml), minute ventilation (in l/min) and FiO2 of the ventilator
displayed as box-and-whisker plots (median, quartile, minimum, maximum). w
p,0,05 compared to day of exchange (day 0).
doi:10.1371/journal.pone.0112316.s003 (TIF)
File S4. Indications and procedures. Description of data: Indication for vv
ECMO, approach to acute system-exchange, infection control and antibiotic
therapy strategies.
doi:10.1371/journal.pone.0112316.s004 (DOCX)
Author Contributions
Conceived and designed the experiments: ML KL AP MF TM DL CS AH GR TB
TBE. Analyzed the data: ML KL AP MF TM DL CS AH GR TB TBE. Contributed
reagents/materials/analysis tools: ML KL AP MF. Wrote the paper: ML KL AP MF
TM DL CS AH GR TB TBE. Read and approved the final manuscript: ML KL AP
MF TM DL CS AH GR TB TBE.
References
1. MacLaren G, Combes A, Bartlett RH (2012) Contemporary extracorporeal membrane oxygenation for
adult respiratory failure: life support in the new era. Intensive Care Med 38: 210–220.
2. Peek GJ, Elbourne D, Mugford M, Tiruvoipati R, Wilson A, et al. (2010) Randomised controlled trial
and parallel economic evaluation of conventional ventilatory support versus extracorporeal membrane
oxygenation for severe adult respiratory failure (CESAR). Health Technol Assess 14: 1–46.
3. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, et al. (2009) Efficacy and economic
assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe
adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 374: 1351–1363.
4. Australia, New Zealand Extracorporeal Membrane Oxygenation Influenza I, Davies A, Jones D,
Bailey M, et al. (2009) Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute
Respiratory Distress Syndrome. JAMA 302: 1888–1895.
5. Combes A, Pellegrino V (2011) Extracorporeal membrane oxygenation for 2009 influenza A (H1N1)-
associated acute respiratory distress syndrome. Semin Respir Crit Care Med 32: 188–194.
Technical Complications during Veno-Venous ECMO
PLOS ONE | DOI:10.1371/journal.pone.0112316 December 2, 2014 21 / 22
6. Napolitano LM, Park PK, Raghavendran K, Bartlett RH (2010) Nonventilatory strategies for patients
with life-threatening 2009 H1N1 influenza and severe respiratory failure. Crit Care Med 38: e74–90.
7. Park PK, Napolitano LM, Bartlett RH (2011) Extracorporeal membrane oxygenation in adult acute
respiratory distress syndrome. Crit Care Clin 27: 627–646.
8. Combes A, Bacchetta M, Brodie D, Muller T, Pellegrino V (2012) Extracorporeal membrane
oxygenation for respiratory failure in adults. Curr Opin Crit Care 18: 99–104.
9. Brogan TV, Thiagarajan RR, Rycus PT, Bartlett RH, Bratton SL (2009) Extracorporeal membrane
oxygenation in adults with severe respiratory failure: a multi-center database. Intensive Care Med 35:
2105–2114.
10. Muller T, Bein T, Philipp A, Graf B, Schmid C, et al. (2013) Extracorporeal pulmonary support in
severe pulmonary failure in adults: a treatment rediscovered. Dtsch Arztebl Int 110: 159–166.
11. Schmid C, Philipp A, Hilker M, Rupprecht L, Arlt M, et al. (2012) Venovenous extracorporeal
membrane oxygenation for acute lung failure in adults. J Heart Lung Transplant 31: 9–15.
12. Lehle K, Philipp A, Gleich O, Holzamer A, Muller T, et al. (2008) Efficiency in extracorporeal
membrane oxygenation-cellular deposits on polymethylpentene membranes increase resistance to
blood flow and reduce gas exchange capacity. ASAIO J 54: 612–617.
13. Sidebotham D, McGeorge A, McGuinness S, Edwards M, Willcox T, et al. (2010) Extracorporeal
membrane oxygenation for treating severe cardiac and respiratory failure in adults: part 2-technical
considerations. J Cardiothorac Vasc Anesth 24: 164–172.
14. Byrnes J, McKamie W, Swearingen C, Prodhan P, Bhutta A, et al. (2011) Hemolysis during cardiac
extracorporeal membrane oxygenation: a case-control comparison of roller pumps and centrifugal
pumps in a pediatric population. ASAIO J 57: 456–461.
15. Lehle K, Philipp A, Muller T, Schettler F, Bein T, et al. (2013) Flow Dynamics of Different Adult ECMO
Systems: A Clinical Evaluation. Artif Organs.
16. Yu K, Long C, Hei F, Li J, Liu J, et al. (2011) Clinical evaluation of two different extracorporeal
membrane oxygenation systems: a single center report. Artif Organs 35: 733–737.
17. Lubnow M, Philipp A, Dornia C, Schroll S, Bein T, et al. (2013) d-dimers as an early marker for
oxygenator exchange in extracorporeal membrane oxygenation. J Crit Care.
18. Kuehn C, Orszag P, Burgwitz K, Marsch G, Stumpp N, et al. (2013) Microbial adhesion on membrane
oxygenators in patients requiring extracorporeal life support detected by a universal rDNA PCR test.
ASAIO J 59: 368–373.
19. Muller T, Lubnow M, Philipp A, Schneider-Brachert W, Camboni D, et al. (2011) Risk of circuit
infection in septic patients on extracorporeal membrane oxygenation: a preliminary study. Artif Organs
35: E84–90.
20. Allen S, Holena D, McCunn M, Kohl B, Sarani B (2011) A review of the fundamental principles and
evidence base in the use of extracorporeal membrane oxygenation (ECMO) in critically ill adult patients.
J Intensive Care Med 26: 13–26.
21. Hill JD, O’Brien TG, Murray JJ, Dontigny L, Bramson ML, et al. (1972) Prolonged extracorporeal
oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome). Use of the Bramson
membrane lung. N Engl J Med 286: 629–634.
22. Conrad SA, Rycus PT, Dalton H (2005) Extracorporeal Life Support Registry Report 2004. ASAIO J 51:
4–10.
23. Kniazeva T, Epshteyn AA, Hsiao JC, Kim ES, Kolachalama VB, et al. (2012) Performance and
scaling effects in a multilayer microfluidic extracorporeal lung oxygenation device. Lab Chip 12: 1686–
1695.
24. Nolan H, Wang D, Zwischenberger JB (2011) Artificial lung basics: fundamental challenges, alternative
designs and future innovations. Organogenesis 7: 23–27.
25. Chauhan S, Subin S (2011) Extracorporeal membrane oxygenation, an anesthesiologist’s perspective:
physiology and principles. Part 1. Ann Card Anaesth 14: 218–229.
26. Dornia C, Philipp A, Bauer S, Hoffstetter P, Lehle K, et al. (2013) Visualization of thrombotic deposits
in extracorporeal membrane oxygenation devices using multidetector computed tomography: a
feasibility study. ASAIO J 59: 439–441.
Technical Complications during Veno-Venous ECMO
PLOS ONE | DOI:10.1371/journal.pone.0112316 December 2, 2014 22 / 22
